🏥CMS Information Collection Activities Notice and Implications for Businesses
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Learn More🏥Notice of National Research Advisory Council Meeting - VA
The Department of Veterans Affairs announces a meeting for the National Research Advisory Council (NRAC) to discuss research policies affecting Veterans' health care. The meeting will include public comments and presentations from various committees, with an option for virtual participation. Public statements can be submitted in advance for review.
Learn More🏥Medicare and Medicaid 2026 Updates
The regulatory document outlines updates to the Home Health Prospective Payment System (HH PPS) and the Quality Reporting Program for 2026, alongside changes to the Durable Medical Equipment Competitive Bidding Program. These updates aim to streamline compliance and enhance service delivery in the healthcare sector, impacting various stakeholders, including providers and patients.
Learn More🎓Nurse Corps Scholarship Program OMB Review Notice
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
Learn More🍀FDA Issues Priority Review Voucher for Rare Pediatric Drug
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that MODESYO (dordaviprone), approved August 6, 2025, manufactured by Chimerix, Inc., meets the criteria for a priority review voucher.
Learn More📋National Sample Survey of Registered Nurses
The Department of Commerce is seeking public comments on the National Sample Survey of Registered Nurses, aimed at collecting data to evaluate the characteristics and distribution of registered nurses in the U.S. The initiative addresses the evolving dynamics of the nursing workforce and includes modifications to the survey methods and content for the next collection cycle.
Learn More💊FDA Announces Regulatory Review Determination for OHTUVAYRE
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OHTUVAYRE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.
Learn More💊FDA Notice on Patent Extension for IQIRVO Drug Review Period
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IQIRVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Learn More💊FDA Notice on LUMISIGHT Patent Extension Review Period
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMISIGHT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Learn More⚖️FINRA Accelerates Arbitration for Elderly and Health-Affected Parties
The FINRA proposed rule change aims to accelerate arbitration proceedings for parties aged 70 and over or those with specific health conditions. This initiative seeks to ensure that these individuals can participate meaningfully in the arbitration process, enhancing outcomes reflective of their claims while maintaining flexibility for arbitrators in scheduling and case management.
Learn More